T1	p 81 134	postmenopausal breast cancer survivors with bone loss
T2	p 381 445	223 postmenopausal breast cancer survivors . Subjects who were >
T3	p 582 628	) postmenopausal breast cancer survivors ( BCS
T4	p 636 645	bone loss
T5	p 764 773	, femoral
T6	p 858 892	2 ) subjects who also participated
T7	p 896 911	strength/weight
T8	p 1016 1026	) subjects
T9	p 1111 1129	Postmenopausal BCS
T10	p 1136 1137	)
T11	p 1429 1455	women who took medications
T12	p 1518 1523	total
T13	p 1639 1646	. Women
T14	p 1732 1741	total hip
T15	p 1970 1980	who were >
T16	p 2047 2052	total
T17	p 2227 2245	postmenopausal BCS
T18	i 20 35	weight training
T19	i 227 261	weight training exercises enhanced
T20	i 283 294	risedronate
T21	i 297 320	calcium , and vitamin D
T22	i 666 677	risedronate
T23	i 680 703	calcium , and vitamin D
T24	i 896 937	strength/weight training ( ST ) exercises
T25	i 1161 1202	to exercise plus medication or medication
T26	i 1263 1270	calcium
T27	i 1279 1300	IU of vitamin D daily
T28	i 1314 1325	risedronate
T29	i 1343 1351	exercise
T30	i 1375 1400	ST exercises twice weekly
T31	i 1623 1626	NTx
T32	i 1863 1866	NTx
T33	i 2165 2199	Strength/weight training exercises
T34	o 39 77	bone mineral density and bone turnover
T35	o 336 377	or improving bone mineral density ( BMD )
T36	o 483 501	improvement in BMD
T37	o 629 645	) with bone loss
T38	o 718 746	bone mineral density ( BMD )
T39	o 760 765	hip ,
T40	o 781 807	L1-L4 spine , total radius
T41	o 826 855	and decreased bone turnover ;
T42	o 960 970	in BMD and
T43	o 989 1007	in bone turnover ;
T44	o 1491 1510	improvements in BMD
T45	o 1524 1527	hip
T46	o 1544 1549	spine
T47	o 1617 1626	serum NTx
T48	o 1691 1697	in BMD
T49	o 1732 1741	total hip
T50	o 1756 1761	spine
T51	o 1776 1788	total radius
T52	o 1857 1866	Serum NTx
T53	o 1891 1923	changes in BMD and bone turnover
T54	o 2036 2039	BMD
T55	o 2100 2107	femoral
T56	o 2217 2223	of BMD
T57	o 2227 2241	postmenopausal
T58	o 2258 2269	bone loss .